- The benefit of luspatercept in the treatment of low‑risk myelodysplastic syndrome – case report2023 | First Faculty of Medicine
- Luspatercept – a new contribution to the therapy of anaemia in patients with myelodysplastic syndrome2023 | First Faculty of Medicine
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial2023 | First Faculty of Medicine
- Luspatercept představuje velký pokrok v terapii anemie u myelodysplastického syndromu2023 | First Faculty of Medicine